» Articles » PMID: 36035305

Exploring Early Physical Examination Diagnostic Biomarkers for Alzheimer's Disease Based on Least Absolute Shrinkage and Selection Operator

Overview
Publisher Hindawi
Date 2022 Aug 29
PMID 36035305
Authors
Affiliations
Soon will be listed here.
Abstract

Neurodegenerative diseases such as Alzheimer's disease (AD) are an increasing public health challenge. There is an urgent need to shift the focus to accurate detection of clinical AD at the physical examination stage. The purpose of this study was to identify biomarkers for AD diagnosis. Differential expression analysis was performed on a dataset including prefrontal cortical samples and peripheral blood samples of AD to identify shared differentially expressed genes (DEGs) shared between the two datasets. In addition, a minimum absolute contraction and selection operator (LASSO) model based on shared-DEGs identified nine signature genes (MT1X, IGF1, DLEU7, TRIM36, PTPRC, WNK2, SPG20, C8orf59, and BRWD1) that accurately predict AD occurrence. Enrichment analysis showed that the signature gene was significantly associated with the AD-related p53 signaling pathway, T-cell receptor signaling pathway, HIF-1 signaling pathway, AMPK signaling pathway, and FoxO signaling pathway. Thus, our results identify not only biomarkers for diagnosing AD but also potentially specific pathways. The AD biomarkers proposed in this study could serve as indicators for prevention and diagnosis during physical examination.

Citing Articles

Identification of altered immune cell types and molecular mechanisms in Alzheimer's disease progression by single-cell RNA sequencing.

Lin H, Su L, Mao D, Yang G, Huang Q, Lan Y Front Aging Neurosci. 2024; 16:1477327.

PMID: 39610716 PMC: 11602448. DOI: 10.3389/fnagi.2024.1477327.


Retracted: Exploring Early Physical Examination Diagnostic Biomarkers for Alzheimer's Disease Based on Least Absolute Shrinkage and Selection Operator.

Methods In Medicine C Comput Math Methods Med. 2023; 2023:9862941.

PMID: 38077916 PMC: 10700805. DOI: 10.1155/2023/9862941.


Exploration of novel biomarkers in Alzheimer's disease based on four diagnostic models.

Zou C, Su L, Pan M, Chen L, Li H, Zou C Front Aging Neurosci. 2023; 15:1079433.

PMID: 36875704 PMC: 9978156. DOI: 10.3389/fnagi.2023.1079433.

References
1.
Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

2.
Guo J, Cheng J, North B, Wei W . Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology. Biochim Biophys Acta Rev Cancer. 2017; 1868(2):341-358. PMC: 5675793. DOI: 10.1016/j.bbcan.2017.07.001. View

3.
Li D, Zheng C, Zhang F, Shi J . Potential neuroprotection by nobile Lindl alkaloid in Alzheimer's disease models. Neural Regen Res. 2021; 17(5):972-977. PMC: 8552836. DOI: 10.4103/1673-5374.324824. View

4.
Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

5.
Serra A, Onlu S, Coretto P, Greco D . An integrated quantitative structure and mechanism of action-activity relationship model of human serum albumin binding. J Cheminform. 2019; 11(1):38. PMC: 6551915. DOI: 10.1186/s13321-019-0359-2. View